Shots:Eric shared the results from the first immunological results of its PDC-LUNG-101 P-I/II trial with PDC*lung01 which is the company’s cancer vaccine candidate for Non-Small Cell Lung CancerThe results were presented at ESMO-IO 2022 elaborating on the safety, tolerability, immunogenicity, and preliminary clinical activity of the drug candidateThe interview shows PDC*line’s vision…

Shots:Monica spoke about the new data from its multiple sclerosis therapies portfolio presented at the 38th ECTRIMS meetingThe highlights from the presentation were the safety and efficacy results of Vumerity, patient-reported outcomes from the treatment with Tysabri, and posters highlighting advances in digital health initiativesThe interview shows how Biogen develops, and delivers…